Beam Therapeutics Inc.'s stock price has seen significant movement, with some outlets reporting gains and others noting a fade in gains despite promising data on a rare liver disease treatment. The company has reported a quarterly loss, but beat revenue estimates. The stock's performance has led to various analyses and comparisons with other gene-editing stocks, as well as changes in stakeholder investments.